Table 3.

Details of PRP treatment protocols and control

Follow-up, mo	WOMAC	No. of Studies	No. of Cases PRP/HA	MD	(95% CI)	Heterogeneity, P; I2	P Value of Effect Size, Z (P)
1	Pain	3	108/114	–	(–0.65 to 0.27)	0.05; 67%	0.80 (0.42)
	Stiffness	2	58/64	−0.13	(–0.41 to 0.15)	0.21; 35%	0.89 (0.37)
	Function	2	58/64	−2.35	(–5.28 to 0.57)	0.12; 59%	1.57 (0.12)
	Total	3	119/124	−3.81	(–7.98 to 0.36)	0.03; 71%	1.79 (0.07)
3	Pain	4	129/138	−0.31	(–1.16 to 0.54)	<0.0001; 88%	0.72 (0.47)
	Stiffness	3	80/88	−0.35	(–0.63 to −0.08)	0.44; 0%	2.50 (0.01)
	Function	4	80/88	−1.92	(–2.57 to −1.27)	0.80; 0%	5.82 (<0.000001)
	Total	5	155/163	−5.02	(–10.79 to 0.76)	<0.00001; 89%	1.70 (0.09)
6	Pain	6	270/263	−1.24	(–1.94 to −0.53)	<0.0001; 83%	3.42 (0.0006)
	Stiffness	5	221/213	−0.46	(–0.92 to 0.01)	0.04; 60%	1.93 (0.05)
	Function	5	221/213	−3.71	(–7.21 to −0.22)	<0.0001; 84%	2.08 (0.04)
	Total	7	296/288	−10.78	(–17.51 to −4.04)	<0.00001; 94%	3.13 (0.002)
12	Pain	5	232/218	−1.75	(–2.50 to −1.01)	<0.00001; 89%	4.61 (<0.000001)
	Stiffness	4	183/168	−0.99	(–1.57 to −0.42)	0.001; 81%	3.40 (0.0007)
	Function	4	183/168	−8.90	(–14.82 to −2.99)	<0.00001; 94%	2.95 (0.003)
	Total	4	183/168	−12.11	(–20.21 to −4.01)	<0.00001; 94%	2.93 (0.003)